MARK1 and prostate cancer: Eight pathways included immune and inflammatory processes (amoebiasis, prostate cancer, rheumatoid arthritis, relaxin, viral protein interaction with cytokine and cytokine receptor, MARK signalling, AMPK signalling, and PI3K-Akt signalling).